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Back to Square One?*Javier Sanz, MDSEE PAGES 1643 AND 1657P revious guidelines for cardiovascular riskassessment recommended the use of a modi-ﬁed Framingham score to estimate the 10-
year risk of hard coronary heart disease (CHD) events,
deﬁned as myocardial infarction and CHD death (1).
Coronary artery calcium (CAC) scoring for reﬁned
stratiﬁcation received Class IIa or IIb recommenda-
tions for those at intermediate (10% to 20%) or low
to intermediate (6% to 10%) risk, respectively (2). In
2013, the American College of Cardiology (ACC) and
American Heart Association (AHA) released guide-
lines (3,4) endorsing new sex- and race-speciﬁc pre-
dictive equations derived from 5 large prospective
cohorts, using conventional risk factors, and esti-
mating 10- or 30-year risks of major atherosclerotic
cardiovascular disease (ASCVD) events (also in-
cluding stroke). The new guidelines advocate initia-
tion or consideration of statin therapy based on
absolute 10-year risk thresholds of $7.5% or 5%
to 7.5%, respectively, as determined by these equa-
tions. CAC scoring is considered if uncertainty
remains after conventional risk assessment (Class
IIb recommendation).
Notably, whether CAC (or other markers) continue
to provide meaningful prognostic information when
these new equations are used needs revisiting (5). In
this issue of the Journal, investigators from MESA
(the Multi-Ethnic Study of Atherosclerosis) address
this relevant question (6), primarily by evaluating the*Editorials published in the Journal of the American College of Cardiology
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eligible to a statin-noneligible risk category. Nasir
et al. (6) included 4,758 individuals comparable to
those targeted in the new guidelines: 45 to 75 years of
age, no previous cardiovascular disease or baseline
lipid-lowering therapy, and low-density lipoprotein
(LDL) cholesterol >70 mg/dl. Applying the updated
equations, statins would have been “recommended”
in 2,377 participants (50%) due to LDL $190 mg/dl
(2%), diabetes and LDL 70 to 189 mg/dl (10%), or
estimated 10-year risk $7.5% (38%) and “considered”
in 12% of participants with 10-year risk of 5% to 7.5%.During a median follow-up of 10.3 years, CAC scoring
demonstrated discriminatory predictive ability across
the 3 groups of statin “recommended,” “considered,”
and “not recommended,” with respective ASCVD
event rates of 5.2%, 1.5%, and 1.3% for those with a
CAC score of 0, and 15%, 6%, and 9.6% if the Agatston
CAC score was $100.
This important study conﬁrms that, in the current
era of updated and presumably improved predictive
scores (7), CAC retains a strong ability to reclassify
cardiovascular risk. In addition, it addresses a critical
issue and represents a step in the right direction: in
an environment with limited resources, efforts
should be made to identify not only newer in-
dications for therapy but also those who may not
signiﬁcantly beneﬁt from it. In the case of statins for
primary ASCVD prevention, the absence of CAC may
represent such a tool, based on the data presented in
this paper and also in Framingham cohorts (7). The
study also raises, among others, several relevant
questions.
Should we now use CAC scoring to screen for sub-
clinical CHD? The authors contend that those with an
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1670intermediate (5% to 20%) 10-year risk would be most
likely to beneﬁt from CAC scoring, and we agree. In
the group “not recommended” for statins, the very
low 10-year event rate (1.2%) argues against the need
for further stratiﬁcation. Even though those with a
CAC score $100 had a 10-year risk of almost 10%, they
represented only 4% of the group, and generalized
scanning would likely be unjustiﬁed. In addition,
these high rates should be taken with caution given
that they derive from only 7 events. In the “statin-
recommended” group as a whole, a CAC score of
0 was associated with a 5.2% event rate, not enough
to reach the “no-statin” threshold under the new
guidelines. The event rate of almost 12% in those with
a very high ($20%) risk despite the absence of calci-
ﬁcation is well above the guideline-based threshold
for therapy, so CAC scoring in this subgroup would
not change management. Conversely, of those with
10-year risks of 7.5% to 20% (excluding individuals
with LDL $190 mg/dl or diabetes), absent CAC may
indicate a sufﬁciently reduced risk to consider
withholding statins. Finally, measuring CAC could
be reasonable in the “statin-considered” group (5%
to 7.5% risk) given that this is relatively small (12%),
a CAC score of 0 is common (57%), and it
signiﬁcantly downgrades 10-year risk (1.5% vs. 6.3%
to 7.8%). However, if statins are not recommended
below the 5% threshold and since the overall
event rate was 4% in this group, CAC scoring would
not be needed to begin with. Thus, based on this
study, it could be argued that in the latter 2 groups,
CAC scoring might deserve Class IIa and IIb
recommendations, respectively: strikingly similar to
the older guidelines.
Should we then measure CAC in all intermediate-
risk individuals? The data presented by Nasir et al.
(6) does not answer this question, but we would argue
against it. First, CAC scoring is not without cost or
(hypothetical) risks. Although, as pointed out by the
authors, it may be cost-effective in the intermediate-
risk U.S. population, cost-effectiveness models are
based on multiple assumptions and extrapolations,
are sensitive to numerous confounders, and cannot
be generalized to other health environments. Second,
if intermediate-risk individuals are willing to take
statins (under the new guidelines), there seems to be
little reason to recommend CAC scoring to prevent
them from doing it. Third, the overestimation of risk
with the new equations, reported in MESA and other
populations (8) argues for the need of recalibration (5)
and questions the comparison of CAC with a “sub-
optimal” standard. Fourth, the potential beneﬁt of
CAC-driven statin therapy is based on assumptions of
consistent and predictable statin efﬁcacy. Althoughmeta-analyses suggest an average risk reduction in
the vicinity of 25% (9), there is substantial heteroge-
neity among primary prevention trials. Finally, and
most importantly, a screening tool is generally
considered justiﬁed when it can trigger an interven-
tion of proven beneﬁt in a speciﬁc context. Unfortu-
nately, conclusive evidence that statins reduce
events in those with elevated CAC scores does not
exist. Class I evidence of conventional risk-driven
statin therapy is similarly lacking, but this hardly
justiﬁes replacing an unproven method with another,
particularly when one is almost universally available,
and the other is not. However, in individual cases of
borderline or uncertain risk, personal concerns, or
statin side effects or disutility, CAC scoring probably
remains the best tool that we have today to guide
management.
Should we tailor statin therapy using CAC scoring?
If one accepts the premise that statins are indicated
based on absolute-risk thresholds, this seems
reasonable. Although not in the high-risk group, the
data from Nasir et al. (6) provide reassurance that
withholding statins in those with a CAC score of
0 may likely be safe, at least in the midterm. In
addition, the CAC score could be an important gate-
keeper to avoid statin overtreatment if conventional
scores overestimate risk. This editorialist also be-
lieves that individuals with a high CAC score (the
deﬁnition of which remains debatable) would beneﬁt
from statins. The powerful prognostic implications of
the CAC score as well as the substantial heterogeneity
and ever-changing risk proﬁles of populations would
thus support a more prominent role of CAC (as a
marker of subclinical CHD) in routine stratiﬁcation,
which could be accomplished by integrating CAC re-
sults into risk scores, as recently proposed and vali-
dated (10). However, we have numerous recent
examples of very reasonable hypotheses that are
disproved when tested formally. Regarding CAC,
numbers needed to treat (and cost-effectiveness) are
estimated based on the assumption of similar relative
risk reductions with statins in lower and higher risk
groups; however, actual data suggest that relative
beneﬁt is in fact highest in the lowest risk categories
(11). The same could be true across CAC strata.
For CAC scoring or other markers, including the
new equations, to achieve Class I (or III) recommen-
dations in clinical guidelines, all these questions will
need to be addressed in a properly designed, pro-
spective, randomized clinical trial. We therefore join
our voice to that of the authors and others (12,13)
encouraging the National Institutes of Health,
perhaps in partnership with industry, to lead this
effort. Although such an enterprise will undoubtedly
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1671be daunting and costly, will not be perfect, and will
not provide all answers, few prevention trials could
have a broader impact on the population at large.
Alternatively, we can continue to speculate, as-
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